ASX Share rice
Tue 11 May 2021 - 06:08:pm (Sydney)

CDY Share Price

CELLMID LIMITEDCDYPharmaceuticals, Biotechnology & Life Sciences

CDY Company Information


Cellmid Limited





GIC Industry:


GIC Sub Industry:



55 Clarence Street Sydney NSW Australia 2000


61 2 9221 6830

CEO, MD & Exec. Director:

Ms. Maria Halasz

Managing Director of Advangen Inc:

Mr. Koichiro Koike

Group Financial Controller:

Mr. Matthew Dudek

Chief Operating Officer:

Mr. Dominic Burg

Head of R&D:

Dr. Graham Robertson

Global Head of Marketing Advangen Pty Ltd:

Ms. Trish Frelan

Company Sec.:

Mr. Lee Tamplin B.A.

Company Overview:

Cellmid Limited, a life sciences company, researches, develops, and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers midkine, a driver and modulator of inflammatory diseases, including chronic inflammatory diseases and cancer; and focuses on blocking midkine, a protein for autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer, and neurodegenerative diseases. It also develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company sells SARS-CoV-2 antibody kits and PCR tests. It markets its products through retailers and wholesalers, as well as through a direct-to-consumer e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.

CDY Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


CDY CashFlow Statement

CashFlow Date:


Change To Liabilities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Change To Inventory:


Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


CDY Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Other Operating Expenses:


Interest Expense:


Income Tax Expense:


Total Revenue:


Cost Of Revenue:


CDY Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:


Other Liabilities:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Total Current Assets:


Long-Term Debt:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Short-Term Investments:


Non Current Liabilities Total:


CDY Share Price History

CDY News

29 Sep, 2020
This article will reflect on the compensation paid to Maria Halasz who has served as CEO of Cellmid Limited (ASX:CDY...